• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

临床药物遗传学实施联盟指南（CPIC）：CYP2C9 与非甾体类抗炎药。

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.

机构信息

Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.

出版信息

Clin Pharmacol Ther. 2020 Aug;108(2):191-200. doi: 10.1002/cpt.1830. Epub 2020 Apr 28.

DOI:10.1002/cpt.1830
PMID:32189324
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8080882/
Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used analgesics due to their lack of addictive potential. However, NSAIDs have the potential to cause serious gastrointestinal, renal, and cardiovascular adverse events. CYP2C9 polymorphisms influence metabolism and clearance of several drugs in this class, thereby affecting drug exposure and potentially safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for NSAIDs based on CYP2C9 genotype (updates at www.cpicpgx.org).

摘要

非甾体抗炎药（NSAIDs）由于缺乏成瘾性而成为最常用的镇痛药之一。然而，NSAIDs 有可能引起严重的胃肠道、肾脏和心血管不良事件。CYP2C9 多态性影响该类药物的代谢和清除，从而影响药物暴露和潜在的安全性。我们总结了来自已发表文献的证据，支持这些关联，并根据 CYP2C9 基因型为 NSAIDs 提供治疗建议（www.cpicpgx.org 更新）。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9f0/8080882/b15b09ac30fe/nihms-1687646-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9f0/8080882/b15b09ac30fe/nihms-1687646-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9f0/8080882/b15b09ac30fe/nihms-1687646-f0001.jpg

相似文献

1
Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.临床药物遗传学实施联盟指南（CPIC）：CYP2C9 与非甾体类抗炎药。
Clin Pharmacol Ther. 2020 Aug;108(2):191-200. doi: 10.1002/cpt.1830. Epub 2020 Apr 28.
2
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.临床药物遗传学实施联盟（CPIC）关于二氢嘧啶脱氢酶基因型和氟嘧啶剂量的指南：2017 年更新。
Clin Pharmacol Ther. 2018 Feb;103(2):210-216. doi: 10.1002/cpt.911. Epub 2017 Nov 20.
3
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.临床药物基因组学实施联盟 (CPIC) CYP2C9 和 HLA-B 基因型与苯妥英钠剂量指南：2020 年更新。
Clin Pharmacol Ther. 2021 Feb;109(2):302-309. doi: 10.1002/cpt.2008. Epub 2020 Sep 6.
4
Application of pharmacogenetics in clinical practice: problems and solutions.临床实践中药物遗传学的应用：问题与对策。
J Neural Transm (Vienna). 2019 Jan;126(1):109-113. doi: 10.1007/s00702-018-1894-0. Epub 2018 Jun 19.
5
Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.临床药物基因组学实施联盟关于CYP2C9和HLA - B基因型与苯妥英钠给药的指南。
Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6.
6
An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.对 5408 名澳大利亚患者 CYP2D6、CYP2C19、CYP2C9 和 VKORC1 基因进行基因分型后的等位基因、基因型和表型频率、可操作的药物基因组学 (PGx) 变异体和表型转化分析。
J Neural Transm (Vienna). 2019 Jan;126(1):5-18. doi: 10.1007/s00702-018-1922-0. Epub 2018 Sep 6.
7
Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on MT-RNR1 Genotype.临床药物遗传学实施联盟基于 MT-RNR1 基因型指导使用氨基糖苷类药物。
Clin Pharmacol Ther. 2022 Feb;111(2):366-372. doi: 10.1002/cpt.2309. Epub 2021 Jun 20.
8
Health regulatory communications of well-established safety-related pharmacogenomics associations in six developed countries: an evaluation of alignment.六个发达国家中已确立的与安全性相关的药物基因组学协会的健康监管沟通：一致性评估
Pharmacogenomics J. 2017 Mar;17(2):121-127. doi: 10.1038/tpj.2016.5. Epub 2016 Feb 23.
9
An update on the pharmacogenomics of NSAID metabolism and the risk of gastrointestinal bleeding.非甾体抗炎药代谢的药物基因组学与胃肠道出血风险的最新进展。
Expert Opin Drug Metab Toxicol. 2020 Apr;16(4):319-332. doi: 10.1080/17425255.2020.1744563. Epub 2020 Mar 29.
10
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y Receptor Inhibitor Treatment in Percutaneous Coronary Intervention.更新的血小板功能和基因检测指导经皮冠状动脉介入治疗中 P2Y 受体抑制剂治疗的专家共识声明。
JACC Cardiovasc Interv. 2019 Aug 26;12(16):1521-1537. doi: 10.1016/j.jcin.2019.03.034. Epub 2019 Jun 12.

引用本文的文献

1
The Role of Pharmacogenetic Biomarkers in Pain.药物遗传生物标志物在疼痛中的作用。
Biomedicines. 2025 Aug 8;13(8):1935. doi: 10.3390/biomedicines13081935.
2
Choosing a nonsteroidal anti-inflammatory drug for pain.选择一种用于止痛的非甾体抗炎药。
Aust Prescr. 2025 Aug;48(4):139-144. doi: 10.18773/austprescr.2025.032.
3
Association between proton pump inhibitors and anti-coagulants for a better prevention of gastrointestinal bleeding.质子泵抑制剂与抗凝剂联合使用以更好地预防胃肠道出血。

本文引用的文献

1
Retained duplications and deletions of CYP2C genes among primates.灵长类动物 CYP2C 基因的保留重复和缺失。
Mol Phylogenet Evol. 2018 Aug;125:204-212. doi: 10.1016/j.ympev.2018.03.037. Epub 2018 Apr 6.
2
Cyclooxygenase Inhibition: Pain, Inflammation, and the Cardiovascular System.环氧化酶抑制：疼痛、炎症与心血管系统。
Clin Pharmacol Ther. 2017 Oct;102(4):611-622. doi: 10.1002/cpt.794. Epub 2017 Aug 17.
3
Widespread Use of Prescription Nonsteroidal Anti-Inflammatory Drugs Among U.S. Army Active Duty Soldiers.美国现役军人中处方非甾体抗炎药的广泛使用。
Med Pharm Rep. 2025 Jul;98(3):333-341. doi: 10.15386/mpr-2767. Epub 2025 Jul 30.
4
Next-Generation Approaches in Sports Medicine: The Role of Genetics, Omics, and Digital Health in Optimizing Athlete Performance and Longevity-A Narrative Review.运动医学的下一代方法：遗传学、组学和数字健康在优化运动员表现和寿命方面的作用——一篇叙述性综述。
Life (Basel). 2025 Jun 27;15(7):1023. doi: 10.3390/life15071023.
5
Pharmacologic Management of Patent Ductus Arteriosus in the Neonatal Intensive Care Unit: A Retrospective Study.新生儿重症监护病房中动脉导管未闭的药物治疗：一项回顾性研究
J Pediatr Pharmacol Ther. 2025 Apr;30(2):250-257. doi: 10.5863/1551-6776-30.2.250. Epub 2025 Apr 14.
6
Clinician Experiences at the Frontier of Pharmacogenomics and Future Directions.临床医生在药物基因组学前沿的经验与未来方向
J Pers Med. 2025 Jul 7;15(7):294. doi: 10.3390/jpm15070294.
7
Major Allele Frequencies in and in Asian and European Populations: A Case Study to Disaggregate Data Among Large Racial Categories.亚洲和欧洲人群中[具体内容]的主要等位基因频率：一项在大型种族类别中分解数据的案例研究。
J Pers Med. 2025 Jun 27;15(7):274. doi: 10.3390/jpm15070274.
8
Preventing adverse drug reactions and more: current clinical use of pharmacogenetic testing.预防药物不良反应及更多：药物遗传学检测的当前临床应用
Med Genet. 2025 Jul 17;37(3):197-206. doi: 10.1515/medgen-2025-2019. eCollection 2025 Jul.
9
Association of Pharmacogenotyping and Patient-Reported Outcomes in Chronic Pain Management.慢性疼痛管理中药理基因分型与患者报告结局的关联
Health Serv Insights. 2025 Jul 12;18:11786329251356560. doi: 10.1177/11786329251356560. eCollection 2025.
10
Utilisation of drugs with pharmacogenetic recommendations in children in Switzerland.瑞士儿童使用具有药物遗传学推荐的药物情况。
Pharmacogenomics J. 2025 Jul 11;25(4):19. doi: 10.1038/s41397-025-00378-x.
Mil Med. 2017 Mar;182(3):e1709-e1712. doi: 10.7205/MILMED-D-16-00183.
4
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.临床药物基因组学实施联盟（CPIC）华法林给药的药物基因组学指导原则：2017年更新版
Clin Pharmacol Ther. 2017 Sep;102(3):397-404. doi: 10.1002/cpt.668. Epub 2017 Apr 4.
5
Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers.性别以及CYP2C9和CYP2C8基因多态性对布洛芬对映体药代动力学的影响。
Pharmacogenomics. 2015;16(9):939-48. doi: 10.2217/pgs.15.40. Epub 2015 Jun 30.
6
CYP2C9 genotype vs. metabolic phenotype for individual drug dosing--a correlation analysis using flurbiprofen as probe drug.用于个体药物剂量计算的CYP2C9基因型与代谢表型——以氟比洛芬为探针药物的相关性分析
PLoS One. 2015 Mar 16;10(3):e0120403. doi: 10.1371/journal.pone.0120403. eCollection 2015.
7
Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects.CYP2C9*1/*3基因型对韩国受试者中氟比洛芬药代动力学的影响。
Arch Pharm Res. 2015 Jun;38(6):1232-7. doi: 10.1007/s12272-015-0580-0. Epub 2015 Feb 25.
8
Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.临床药物基因组学实施联盟关于CYP2C9和HLA - B基因型与苯妥英钠给药的指南。
Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6.
9
Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals.CYP2C9*3/*3 个体中，美洛昔康的暴露量显著增加。
Pharmacogenet Genomics. 2014 Feb;24(2):113-7. doi: 10.1097/FPC.0000000000000025.
10
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.非甾体抗炎药的血管和上消化道作用：来自随机试验的个体参与者数据的荟萃分析。
Lancet. 2013 Aug 31;382(9894):769-79. doi: 10.1016/S0140-6736(13)60900-9. Epub 2013 May 30.